
Published On: Mar 2021
Published On: Mar 2021
According to a new market research study of ‘North America cell line development Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by type, product, and application’ the North America cell line development market is expected to reach US$ 3,849.54 million in 2027 from US$ 1,401.23 million in 2019. The market is estimated to grow with a CAGR of 13.6% from 2020-2027. The report provides trends prevailing in the North America cell line development market and the factors driving market along with those that act as hindrances.
Based on type, the cell line development market is segmented into primary cell line, hybridomas, continuous cell lines, and recombinant cell line. The recombinant cell line sensor segment held the largest share of the market in 2019, whereas the hybridomas segment is anticipated to register the highest CAGR in the market during the forecast period. The recombinant cell line segment's growth is fuelled due to the rising demand for recombinant proteins, increasing use of recombinant cell lines for bio therapeutics and growing demand for toxicity testing. Additionally, the hybridomas segments growth is expected to grow at the fastest CAGR during the forecast period due to the increasing demand for production of monoclonal antibodies and rising research and development expenditure of pharmaceutical and biotechnology companies.
The growth of this market is estimated to grow owing to key driving factors such as the high rise in the number of cancer cases across North America and the increasing development in the biotechnology sector. However, the market growth is likely to be hindered owing to the cell line contamination by various microorganisms.
Merck KGaA, General Electric, and Lonza are among the leading companies operating in the North America cell line development market.
The report segments North America Cell Line Development Market as Follows:
By Type
By Product
By Application
By Country